[ad_1]
Reporter Seo Yoon-Seok, Bio Spectator
As a result of the analysis of 170 confirmed corona cases19, only 8 vaccines .. 94% or more prevention efficiency for the elderly over 65 years.
Pfizer / BioNtech confirmed a 95% vaccine efficacy rate in the final efficacy analysis of phase III of the COVID-19 vaccine. In particular, the effectiveness of prevention was higher than 94% even in people over 65 years of age.
Pfizer plans to apply for emergency use approval (US) “in a few days” by meeting the two-month safety standard required by the US Food and Drug Administration (FDA).
On the 18th (local time), Pfizer revealed the final analysis result showing that ‘BNT162b2’ showed 95% prevention efficacy in phase 3 clinical trials of a COVID-19 candidate vaccine.
According to the announcement, Pfizer had only 8 vaccination groups of the 170 confirmed corona19 cases that occurred among the subjects. The remaining 162 people were vaccinated with placebo and Pfizer had a 95% prevention efficiency (p
In particular, Pfizer revealed that prevention efficiency was more than 94% in the elderly 65 years and older, and that it observed a consistent effect between age, gender and race.
Pfizer explained that so far 40,3661 subjects have been enrolled in phase 3 clinical trials of BNT162b2, of which 41,135 (based on 13 days) have completed the second dose. The Pfizer vaccine is given twice every 21 days.
Pfizer said it has also met the safety standards required by the FDA. Grade 3 adverse reactions with an incidence of 2% or more after administration of the vaccine were fatigue (3.8%) and headache (2%). Pfizer will continue to track subject efficacy and safety data for a further two years.
After completing the analysis of the research results, Pfizer plans to publish efficacy and safety data in academic journals.
Meanwhile, Pfizer / Bioentech predicts that it will be able to produce COVID-19 vaccines of up to 50 million doses in 2020 and 1.3 billion doses in 2021.
[ad_2]
